Day: February 6, 2024

All-New Volvo VNL PowertrainWith the new Volvo VNL, Volvo Trucks North America extended their class-leading fuel efficiency by enhancing the dependable Volvo D13 engine and I-Shift transmission.Greensboro, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) — With the announcement of the all-new Volvo VNL, the truck designed to change everything, Volvo Trucks North America further extended its class-leading fuel efficiency by enhancing the dependable Volvo D13 engine and I-Shift transmission. Design enhancements to the D13 engine include a new wave piston with a shorter piston height, as well as a longer connecting rod; smaller injector needle control valves; a variable vane oil pump; and improvements to the turbo compounding (TC) unit and turbocharger. To further drive the fuel efficiency benefits of I-Shift, Volvo Trucks engineers...

ARway.ai The Spatial Computing Company Launches Apple Vision Pro Compatibility and Early Access for ARwayKit SDK TORONTO, Feb. 06, 2024 (GLOBE NEWSWIRE) — via IBN– ARway.ai (“ARway” or the “Company”) (CSE: ARWY), (OTC: ARWYF) (FSE: E65) is an AI powered Augmented Reality Experience platform with a disruptive no-code, no beacon spatial computing solution enabled by visual marker tracking with centimeter precision is pleased to announce it has launched its compatibility with Apple’s Vision Pro alongside the revolutionary headset’s recent release on February 2. In addition, the Company is now accepting submissions for their early access list for the ARwayKit SDK for the Apple Vision Pro. The user-friendly ARwayKit SDK will provide a cross-platform developer tool across iOS and RealityOS enabling access to apps with location-persistent...

TORONTO, Feb. 06, 2024 (GLOBE NEWSWIRE) — via IBN — Toggle3D.ai (the “Company”) (CSE:TGGL) (OTC:TGGLF) (FSE:Q0C), a revolutionary AI solution harnessing the power of generative AI to convert CAD files, apply stunning 4K texturing, and seamlessly publish superior 4K 3D models is set to redefine the 3D texturing landscape with its unparalleled speed and user-friendly interface. The Company is using Toggle3D to texture 3D models for Amazon as well as other customers, and is increasing artists’ productivity speed by 100%, providing tangible benefits by reducing the time and cost of 3D model production. The company sees a big economic benefit for the rapidly growing 3D modeling industry for ecommerce which is massive. By using Toggle 3D artists are able to increase profit margins by as much as 50%. Toggle’s...

HBC Immunology Inc. (70.6% owned by Hofseth BioCare ASA) reports today the successful completion of the first in vivo study within its prostate cancer development program. The study assessed whether the combination of targeted hormonal therapy, bicalutamide, and FT-002 or FT-005 was better at suppressing PC3 tumour growth compared to control (no treatment). PC3 represents a model of very aggressive prostate cancer which is resistant to standard treatment. The FT peptides are HBCI’s two leading drug candidates, and both slowed tumour growth. By the end of the study mean tumour volumes were significantly smaller with FT-005 treatment (p

Data presented at 20th WORLDSymposium™ show progressive reversal of motor deficit and corresponding reduction of neurodegeneration biomarker NfL to level of control arm BETHESDA, Md., Feb. 06, 2024 (GLOBE NEWSWIRE) — Gain Therapeutics, Inc., (Nasdaq: GANX), a clinical-stage biotechnology company leading the discovery and development of the next generation of allosteric small molecule therapies, announces preclinical data demonstrating that its clinical-stage GCase regulator GT-02287 provided neuroprotection and restored motor function in Parkinson’s disease models following delayed administration. The data was accepted as a late-breaker abstract and will be presented at the 20th Annual WORLDSymposium™ being held in San Diego this week. “We believe the data showing complete restoration of motor function in a therapeutic...

DECLARATION OF THE NUMBER OF SHARES AND VOTING RIGHTS Information on the total number of voting rights and of shares representing the share capital(Article 223-16 of the General regulations of the French Financial Market Authority – Autoritédes Marchés Financiers) Quotation place: Euronext ParisCompartiment AISIN code: FR0000031577Date Total number of shares representing the share capital Total number of voting rightsJanuary, 31 2024 8 458 000 Gross total of voting rights : 12 774 410Net total* of voting rights : 12 686 129Net total* = total number of voting rights attached to the total number of shares net of shares with no voting rights. VIRBAC: Shaping the future of animal healthNYSE Euronext – Compartiment A / Code ISIN: FR0000031577 / MNEMO: VIRPCorporate Finance: tel. 33 4 92 08 71 32 / Email: finances@virbac.comWebsite:...

Fans score big on craveable Game Day apps and face the most challenging Monday of the year with the Grand Slam Pack on February 12Denny’s AppetizersDenny’s To-Go Offers Big Game SolutionsSpartanburg, SC, Feb. 06, 2024 (GLOBE NEWSWIRE) — The Big Game is right around the corner, and Denny’s (NASDAQ: DENN), America’s Diner, is ready to feed football fanatics (and Swifties) across the nation. Delicious flavors to fuel fans as they rush into the weekend festivities and scramble back into the office to face the “Mondayest Monday” on February 12 are made to order from the booth or from your couch. From touchdown-worthy appetizers that will score big with your crowd to the Grand Slam® Pack that will cure any post-game blues, Denny’s has your game-day needs covered! BE PREPARED FOR THE BIG GAME: Win with your crew,...

NORWOOD, Mass., Feb. 06, 2024 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will provide a corporate update and participate in one-on-one investor meetings at the Oppenheimer 34th Annual Healthcare Life Sciences Conference, to be held virtually February 13-14, 2024. Oppenheimer 34th Annual Healthcare Life Sciences ConferenceFormat: Presentation and one-on-one investor meetingsPresentation Date: Wednesday, February 14, 2024Presentation Time: 8:40 a.m. ETWebcast: Click Here Please contact your Oppenheimer sales representative to register for the conference. About Corbus Corbus Pharmaceuticals Holdings, Inc. is a precision oncology company with a diversified portfolio and is committed to helping people...

RALEIGH, N.C., Feb. 06, 2024 (GLOBE NEWSWIRE) — Martin Marietta Materials, Inc. (NYSE: MLM) (“Martin Marietta” or the “Company”) will host its fourth-quarter and full-year 2023 earnings conference call on Wednesday, February 14, 2024, at 10:00 a.m. Eastern Time. The Company will release results for the quarter and year ended December 31, 2023, that morning before the market opens. A live, listen-only webcast and supplemental information will be accessible on the Investors section of the Company’s website at www.martinmarietta.com. The conference call may also be accessed by dialing +1 (206) 962-3782 and using conference ID 94062876. Please dial in at least 15 minutes in advance to ensure a timely connection to the call. An on-demand replay will be available on the Company’s website approximately two hours following the conclusion...